RECIST v1.1

Biomarker

Also known as: RECIST v1.1

Related News

Immunome Submits NDA for Varegacestat in Desmoid Tumors After Positive Phase 3 RINGSIDE Trial

Apr 29, 2026

Immunome submitted an NDA to the FDA for varegacestat in desmoid tumors after the Phase 3 RINGSIDE trial showed an 84% reduction in progression risk (HR=0.16) and a 56% objective response rate. The company plans to file in Q2 2026.

KEYTRUDA Plus Chemotherapy Improves Survival in Platinum-Resistant Ovarian Cancer

Mar 02, 2026

Final analysis of Merck's Phase 3 KEYNOTE-B96 trial shows KEYTRUDA plus paclitaxel with or without bevacizumab significantly improved overall survival in platinum-resistant recurrent ovarian cancer patients, reducing death risk by 18%.